IMS Study Says Patent Settlements Have Saved $25.5 Billion Since 2005

Patent settlements between brand and generic drugmakers are not anticompetitive, and in fact are “procompetitive and proconsumer,” Ralph Neas, president and CEO of GPhA said Tuesday, adding that an IMS Institute for Healthcare Informatics report released the same day proves just that.
Drug Industry Daily